

REMARKS

Claims 21-36 stand pending. Due to the duplication of numbering the claims Applicants have amended claims 35-37 so as to correct the typographical error of two claims numbered as claim 34. No new matter has been added by virtue of these amendments.

In response to the restriction requirement, Applicants hereby elect Group I, claims 21-26, directed to a method for screening and identifying a compound which inhibits atherosclerosis or restenosis. The other three groupings by the Examiner are to Group II, claims 27-30, directed to a process for identifying and obtaining a compound for atherosclerosis or restenosis; Group III, claims 31-33 directed to a compound found by the method of claims 21, 25, 2 ; and Group IV, claims 34, 36 directed to a method for treating PAOD. Applicants respectfully traverse the restriction requirement.

Applicants respectfully note that the PDE4D claimed in all four groupings have the same/corresponding special technical features. There is no allegation by the Examiner in the cited art of PDE4D but only rather PDE4 as a target. Accordingly, Applicants respectfully traverse the restriction of its claims into the above mentioned four groups.

Appl. No. 10/552,181
Filed: /Aug. 2, 2006

No further fee is required in connection the filing of this Amendment. If any additional fees are deemed necessary, authorization is given to charge the amount of any such fee to Deposit Account No. 08-2525.

Respectfully submitted,



Attorney for Applicant(s)
Robert P. Hoag
(Reg. No. 39712)
340 Kingsland Street
Nutley, NJ 07110
Telephone (973) 235-4453
Telefax: (973) 235-2363

284317